At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 44 enrolled
Drug / intervention
Lenalidomide +1 moredrug
Likely dose
Lenalidomide 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Study of Everolimus (RAD001) in Combination With Lenalidomide in Patients With Advanced Solid Malignancies Enriched for Renal Cell Carcinoma
In Brief
A Phase 1 clinical trial evaluating Lenalidomide and Everolimus for Solid Organ Malignancies and 2 related conditions. Completed, enrolled 44 participants across 2 sites.
Detailed Summary
The purpose of this study is to study the combination of two anticancer drugs, everolimus (RAD001) and lenalidomide in patients whose cancer is no longer responding to standard treatment or patients who are unable to tolerate the standard treatment for their cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedOct 2010
Primary CompletionNov 2020
TodayJul 2026
First PostedOct 11, 2010
Enrollment StartSep 9, 2010
Primary CompletionNov 5, 2020
TodayJul 2, 2026
Enrollment to primary: 10.2 yearsPosted 15.7 years ago
Interventions
Lenalidomidedrug
Lenalidomide (10mg, 15mg, 20mg or 25mg) once daily by mouth, every day of each 28-day cycle.
Everolimusdrug
5mg or 10mg of everolimus administered once daily by mouth on a once daily continuous dosing schedule for 28 days.